Gerdzole-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Pantoprazole 40mg, designed for the effective management of gastroesophageal reflux disease (GERD) and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system of the gastric parietal cells, providing symptomatic relief from acid-related damage and promoting mucosal healing. The synergistic action of these two agents addresses both the motility dysfunction and acid hypersecretion underlying GERD, offering comprehensive symptom control. Gerdzole-DSR is indicated for conditions including erosive esophagitis, non-erosive reflux disease, and Zollinger-Ellison syndrome, among others. The capsule should be administered orally, preferably before meals, as prescribed by a healthcare professional. Caution is advised in patients with known hypersensitivity to either component, cardiac arrhythmias, or hepatic impairment. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic benefits and minimize potential adverse effects such as headache, dry mouth, or gastrointestinal disturbances.